FDA Decides Against Warnings on Epilepsy Medication Suicide Risk

Email this article to a friend

Printable Version

Articles Related to This Article: • Suicide Prevention Drug Pushing Racket - Part II • Experts say antidepressant drugs cause suicides instead of preventing them • Shootings in Germany, Alabama Underscore Violent Side Effects of Psychiatric Medications NaturalNews Store Specials: • Revolutionary new Hurom Slow Juicer at the lowest price on the 'net + FREE shipping! • Certified Organic Nutiva Hemp Seeds at a huge discount (+ FREE bottle of hemp oil) • Omega-3 rich Chia Seeds at under $5 / lb. See more at the NN store...

(NaturalNews) The FDA has decided against placing new warning labels on anti-seizure medications used to treat epilepsy, in spite of recent findings that those drugs can increase a patient's risk of suicide.

In January, the FDA raised the possibility of labeling 11 anti-seizure drugs with "black box" warnings, after numerous studies linked them to increased risks of suicidal behavior: carbamazepine (marketed as Carbatrol, Equetro, Tegretol and Tegretol XR), felbamate (marketed as Felbatol), gabapentin (marketed as Neurontin), lamotrigine (marketed as Lamictal), levetiracetam (marketed as Keppra), oxcarbazepine (marketed as Trileptal), pregabalin (marketed as Lyrica), tiagabine (marketed as Gabitril), topiramate (marketed as Topamax), valproate (marketed as Depakote, Depakote ER, Depakene and Depacon) and zonisamide (marketed as Zonegran).

The so-called anti-convulsants are used primarily to treat epilepsy, bipolar disorder and migraines.

In early July, the FDA announced its intention to add a black box warning about suicide risk to the drugs' labels. This is the strongest warning that the FDA can place on a product without withdrawing from the market.

The next week, however, an FDA advisory panel recommended against adding a black box warning. While the panel had found, upon review of study data, that there was definitely an association between anti-convulsant use and increased suicide risk, it was concerned that a black box warning might lead to reduced use of the drugs.

"If we have good drugs that are working, we have to be very careful about scaring patients into not taking them," said FDA adviser Rochelle Caplan, of the University of California-Los Angeles.

Following the panel's recommendation, the FDA reversed its position and announced that it would no longer add a black box warning the drugs. The agency's prior advice to doctors still stands, however: to be alert for any changes in the "mood, behavior and actions" of those taking anti-convulsant drugs.

Sources for this story include: www.efluxmedia.com; www.businessweek.com.

Share

Get articles like this delivered to you FREE in our popular email newsletter

Related CounterThink Cartoons:

Related Articles: • Suicide Prevention Drug Pushing Racket - Part II • Experts say antidepressant drugs cause suicides instead of preventing them • Shootings in Germany, Alabama Underscore Violent Side Effects of Psychiatric Medications	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/025221_suicide_epilepsy_drugs.html Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. Embed article link: (copy HTML code below): <a href = "http://www.NaturalNews.com/025221_suicide_epilepsy_drugs.html">FDA Decides Against Warnings on Epilepsy Medication Suicide Risk</a>